Serum lipids and the progression of nephropathy in type 1 diabetes
- PMID: 16443880
- DOI: 10.2337/diacare.29.02.06.dc05-0809
Serum lipids and the progression of nephropathy in type 1 diabetes
Abstract
Objective: Dyslipidemia contributes to the progression of microvascular disease in diabetes. However, different lipid variables may be important at different stages of nephropathy. This study examines the pattern of dyslipidemia associated with the progression of nephropathy in patients with type 1 diabetes.
Research design and methods: A total of 152 patients with type 1 diabetes were recruited in order to represent various phases of nephropathy. Patients were followed for 8-9 years, during which time they received standard care. Renal progression was defined a priori as a doubling in albumin excretion (in patients with normo- or microalbuminuria) or a decline in creatinine clearance (in those with macroalbuminuria). A panel of lipid variables was determined and correlated with indexes of progression.
Results: In patients with normoalbuminuria (n = 66), progression was associated with male sex (P < 0.05), borderline albuminuria (P = 0.02), and LDL-free cholesterol (P = 0.02). In patients with microalbuminuria (n = 51), progression was independently associated with triglyceride content of VLDL and intermediate-density lipoprotein (both P < 0.05). In patients with macroalbuminuria (n = 36), a significant decline in the renal function (>3 ml x min(-1) x year(-1)) was independently associated with poor glycemic control, hypertension, and LDL size (P < 0.05). When all patients with progressive nephropathy were analyzed together, only LDL cholesterol was predictive on multivariate analysis (P < 0.05), which masked the importance of triglyceride enrichment in microalbuminuria.
Conclusions: Lipid variables are associated with progression of diabetic kidney disease, but the relationship is not the same at all stages. This finding has implications for the design of renoprotective strategies and the interpretation of clinical trials in type 1 diabetes.
Similar articles
-
Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy.Pak J Pharm Sci. 2012 Jan;25(1):123-9. Pak J Pharm Sci. 2012. PMID: 22186319
-
Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.Diabetes Care. 2008 Jun;31(6):1165-9. doi: 10.2337/dc07-2306. Epub 2008 Mar 17. Diabetes Care. 2008. PMID: 18346990
-
Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function.Cardiovasc Diabetol. 2016 Jan 7;15:3. doi: 10.1186/s12933-015-0326-9. Cardiovasc Diabetol. 2016. PMID: 26739836 Free PMC article.
-
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.
-
[Effect of blood glucose and blood pressure control on progression of diabetic nephropathy].Wien Klin Wochenschr. 2000 Nov 10;112(21):907-11. Wien Klin Wochenschr. 2000. PMID: 11144004 Review. German.
Cited by
-
Development and external validation of a machine learning model to predict diabetic nephropathy in T1DM patients in the real-world.Acta Diabetol. 2025 Jun;62(6):869-879. doi: 10.1007/s00592-024-02404-z. Epub 2024 Nov 11. Acta Diabetol. 2025. PMID: 39527297
-
Clinical predictive factors in diabetic kidney disease progression.J Diabetes Investig. 2017 Jan;8(1):6-18. doi: 10.1111/jdi.12533. Epub 2016 Jun 8. J Diabetes Investig. 2017. PMID: 27181363 Free PMC article. Review.
-
[Protection of renal function in diabetics].Internist (Berl). 2007 Jul;48(7):686, 688-90, 692 passim. doi: 10.1007/s00108-007-1894-x. Internist (Berl). 2007. PMID: 17579824 Review. German.
-
Exploring the Incidence and Risk Factors of Diabetic Nephropathy in Type 1 Diabetes: Insights from a Retrospective Cohort Study in Northwest China.Diabetes Metab Syndr Obes. 2025 Jul 8;18:2267-2276. doi: 10.2147/DMSO.S527431. eCollection 2025. Diabetes Metab Syndr Obes. 2025. PMID: 40655164 Free PMC article.
-
PPARalpha: an emerging therapeutic target in diabetic microvascular damage.Nat Rev Endocrinol. 2010 Aug;6(8):454-63. doi: 10.1038/nrendo.2010.89. Epub 2010 Jun 22. Nat Rev Endocrinol. 2010. PMID: 20567246 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous